The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATOS | -37.3% | -49.98% | -12.93% | -100% |
| S&P | +16.23% | +94.45% | +14.22% | +389% |
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
There are two likely drivers behind the biotech's share price surge.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 0.0% |
| Market Cap | $107.21M | -28.4% |
| Market Cap / Employee | $7.15M | 0.0% |
| Employees | 15 | 25.0% |
| Net Income | -$8.42M | -39.2% |
| EBITDA | -$9.04M | -27.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $57.97M | -27.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.20% | -11.5% |
| Return On Invested Capital | -34.43% | 19.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.26M | -60.1% |
| Operating Free Cash Flow | -$7.26M | -60.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.38 | 1.61 | 1.22 | 1.64 | -5.75% |
| Price to Tangible Book Value | 2.38 | 1.61 | 1.22 | 1.64 | -5.76% |
| Enterprise Value to EBITDA | -18.23 | -6.76 | -2.93 | -5.45 | -44.70% |
| Return on Equity | -31.3% | -31.4% | -34.9% | -41.7% | 48.77% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
